The Establishment Inspection Report (EIR) issued to Zydus Lifesciences by the U.S. Food and Drug Administration (USFDA) concerning the GMP follow-up inspection at its injectable manufacturing facility in Jarod, Vadodara. This audit was carried out be
On World AIDS Day, the World Health Organization called for urgent action to expand access to new HIV prevention tools, warning that deep cuts to foreign aid have disrupted essential services in many countries. The spotlight is on lenacapavir...
Eli Lilly is rolling out a major Zepbound price cut, lowering the cost of its single-dose vials to make the obesity drug easier for patients to afford. The updated pricing is now live through LillyDirect, the company’s digital health platform...
Himalaya Wellness has teamed up with Unicommerce, one of India’s top e-commerce enablement SaaS platforms, to streamline its online operations and accelerate its omnichannel expansion
.jpeg)
Arth by Emcure, a holistic wellness brand rooted in the philosophy of blending science with nature, has launched a powerful new initiative with cricket icon M.S. Dhoni on the occasion of World Iron Deficiency Day. Titled “Invest in Iron,” the campaig
.jpeg)
Zydus Lifesciences, a global innovation-driven healthcare company, today announced that it has entered into an exclusive licensing and commercialization agreement with RK Pharma Inc of the US for a novel sterile injectable 505(b)(2) oncology supporti
Saviynt, the worldwide leader in AI-driven identity security and governance solutions, revealed that Narayana Health, one of India’s largest and most trusted healthcare networks, has implemented the Saviynt Identity Cloud to upgrade identity
.png)
Eli Lilly and Company is preparing to unveil a slate of new findings at the San Antonio Breast Cancer Symposium (SABCS), running December 9–12. The update shines a spotlight on fresh progress in HR+ breast cancer, the most common form of the...
Solara Active Pharma Sciences Limited has announced that its multi-product API plant in Mangalore, Karnataka has cleared a recent US FDA inspection. The review took place from August 25 to 29, 2025, and the company confirmed today that the Agency...
The FDA is investigating Takeda’s Adzynma after a pediatric patient died following the development of neutralizing antibodies. The probe focuses on post-marketing safety signals and potential risks linked to immunogenicity in cTTP treatment.
.jpg)
.jpg)
, CDSCO.jpg)